The application of Sparstolonin B in treating LPS-induced acute lung injury (ALI) model in mice was found in the reported literature. In addition, no literature was found for acute injury model of pneumonia in rats.

The effective dose of nano-sized Sparstolonin B (nSsnB) administered intratracheally (IT) is 0.625 mg/kg, which can significantly reduce lung inflammation, reduce the levels of pro-inflammatory factors (TNF-α, IL-6), and inhibit the activation of NF-κB signaling pathway (PMID: 40264680).

At the same time, considering the drug failure relationship, it is recommended that Sparstolonin B be administered 1–2 hours before LPS stimulation (PMID: 40264680).

It should be noted that ordinary Sparstolonin B often requires a higher dose for in vivo application due to its poor water solubility (such as intraperitoneal injection of 3–9 mg/kg for liver injury model), but the dose for pneumonia model is not directly reported (PMID: 40264680).

It is recommended to design a preliminary experiment first, and convert the mouse dose (0.625 mg/kg, IT) to rats. It can be adjusted according to the body surface area coefficient.

For specific conversion methods, please refer to [Conversion of different model animals based on BSA] provided by MCE.

https://www.medchemexpress.com/Technical%20Support.htm

If intratracheal administration is not considered and an already operated injection method needs to be selected, the pharmacokinetic properties of the drug need to be considered in advance.

The answer to this question comes from MCE Technical Support.

How to contact us?

• Tel: 609-228-6898
• Fax: 609-228-5909
• E-mail: [email protected]
• Technical Support: [email protected]
• Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA